세계의 허혈성 시신경증 치료 시장 : 산업 분석, 규모, 점유율, 성장, 동향, 예측(2024-2033년)

Ischemic Optic Neuropathy Treatment Market: Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2024-2033

US $ 4,995 ￦ 6,970,000

Unprintable PDF & Excel (Single User License)

PDF, Excel 보고서를 1명만 이용할 수 있는 라이선스입니다. 텍스트의 복사, 인쇄가 불가능합니다.

US $ 7,295 ￦ 10,179,000

PDF & Excel (Multi User License)

PDF, Excel 보고서를 동일 기업 내 5명까지 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

US $ 8,495 ￦ 11,853,000

PDF & Excel (Corporate User License)

PDF, Excel 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트의 Copy&Paste와 인쇄가 가능합니다.

한글목차

Persistence Market Research는 허혈성 시신경증 치료 시장에 대한 종합적인 보고서를 발표했습니다. 본 보고서에서는 시장촉진요인,동향,기회,과제 등의 중요한 시장 역학을 철저히 평가하여 시장 구조에 대한 상세한 인사이트을 제공합니다.

주요 인사이트

• 허혈성 시신경증 치료 시장 규모(2024년) : 2억 1,370만 달러
• 예측 시장 가치(2033년) : 2억 8,660만 달러
• 시장 성장률(복합 연간 성장률(CAGR) 2024년-2033년) : 3.3%

허혈성 시신경증 치료 시장 : 조사 범위

허혈성 시신경증(ION)은 시신경에 대한 혈류 부족이 시력 저하로 이어지는 상태를 말합니다. ION 치료 시장은 병원, 클리닉, 전문 안과 센터, 연구 기관을 대상으로 하며, 약리학적 개입, 외과적 치료, 재활 치료 등 다양한 치료 접근법을 제공합니다.

시장 성장 촉진요인 :

세계의 허혈성 시신경증 치료 시장은 혈관 질환에 걸리기 쉬운 인구의 고령화, ION의 주요 위험 인자인 당뇨병과 고혈압의 유병률 증가, 조기 발견과 개입을 용이하게 하는 화상 진단 기술의 진보 등 여러 요인에 의해 견인되고 있습니다. 게다가, 신규 치료의 효능과 환자 중심의 케어 모델에 대한 의료 종사자의 의식 증가가 시장 확대를 더욱 자극하고 있습니다.

시장 성장 억제요인 :

유망한 성장이 예상되는 반면, 허혈성 시신경증 치료 시장은 제한된 치료 옵션, 고급 치료와 관련된 고액 비용, 지역에 따라 다른 상환 정책 등과 관련된 과제에 직면하고 있습니다. 게다가, 병태의 복잡성과 맞춤 치료 접근법의 필요성은 시장 침투와 치료의 표준화에 어려움을 겪고 있습니다.

시장 기회 :

허혈성 시신경증 치료 시장은 신경보호제나 유전자 치료 등의 신규 치료 타겟에 초점을 맞춘 연구개발이 진행되고 있는 점에서 큰 성장 기회로 축복받고 있습니다. 게다가 제약기업, 학술기관, 의료 제공자가 협력하여 임상시험을 진행하고 혁신적인 치료법을 개발함으로써 시장의 역학과 환자의 결과를 향상시키는 태세가 갖추어지고 있습니다.

이 보고서에서 다루는 주요 질문

• 허혈성 시신경증 치료 시장의 세계의 성장을 가속하는 주요 요인은 무엇인가?
• 허혈성 시신경증 치료 시장 경쟁 구도를 형성하는 치료 접근법과 새로운 기술은 무엇인가?
• 허혈성 시신경증 치료 시장에 기여하는 주요 기업은 어디에서 시장 관련성을 유지하기 위해 어떤 전략을 채택하고 있는가?
• 세계의 허혈성 시신경증 치료 시장의 새로운 동향과 전망은?

목차

제1장 주요 요약

제2장 시장 개요

• 시장 범위/분류
• 시장의 정의/범위/제한
• 포함과 제외

제3장 주요 시장 동향

• 시장에 영향을 주는 주요 동향
• 혁신/개발 동향

제4장 주요 성공 요인

• 약물 클래스 채용 분석
• 주요 규제
• 파이프라인 평가
• 주요 기업에 의한 주요 프로모션 전략
• PESTEL 분석
• Porter's Five Forces 분석
• 밸류체인 분석

제5장 시장 배경

• 거시경제 요인
• 예측 요인- 관련성과 영향
• 시장 역학

제6장 COVID-19 위기 분석

• COVID-19와 영향 분석
  • 약제 클래스별
  • 투여 경로별
  • 질환 유형별
  • 유통 채널별
  • 국가별
• 2024년 시장 시나리오

제7장 세계의 허혈성 시신경증 치료 시장 수요 분석

• 과거 시장 가치 분석(2019년-2023년)
• 현재 및 장래 시장 가치 예측(2024년-2033년)
  • 전년대비 성장 동향 분석
  • 절대액의 기회 분석

제8장 세계의 허혈성 시신경증 치료 시장 분석 : 약제 클래스별

• 소개/주요 조사 결과
• 과거 시장 규모 분석 : 약제 클래스별(2019년-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 약제 클래스별(2024년-2033년)
  • 코르티코스테로이드
  • 대사 길항제
  • 항응고제
  • 세로토닌,노르에피네프린 재흡수 억제제(SNRI)
  • 비스테로이드성 항염증제(NSAID)
• 약제 클래스별 시장의 매력 분석

제9장 세계의 허혈성 시신경증 치료 시장 분석 : 투여 경로별

• 소개/주요 조사 결과
• 과거 시장 규모 분석 : 투여 경로별(2019년-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 투여 경로별(2024년-2033년)
  • 경구
  • 주사 가능
• 투여 경로별 시장의 매력 분석

제10장 세계의 허혈성 시신경증 치료 시장 분석 : 질환 유형별

• 소개/주요 조사 결과
• 과거 시장 규모 분석 : 질병 유형별(2019년-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 질환 유형별(2024년-2033년)
  • 후부 허혈성 시신경증
  • 앞부분 허혈성 시신경증
    • 동맥염성 AION(A-AION)
    • 비동맥염성 AION(NA-AION)
• 질병 유형별 시장의 매력 분석

제11장 세계의 허혈성 시신경증 치료 시장 분석 : 유통 채널별

• 소개/주요 조사 결과
• 과거 시장 규모 분석 : 유통채널별(2019년-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 유통 채널별(2024년-2033년)
  • 병원 약국
  • 소매 약국
  • 약국
  • 온라인 약국
• 유통 채널별 시장의 매력 분석

제12장 세계의 허혈성 시신경증 치료 시장 분석 : 지역별

• 소개
• 과거 시장 규모 분석 : 지역별(2019년-2023년)
• 현재 및 장래 시장 규모 분석과 예측 : 지역별(2024년-2033년)
  • 북미
  • 라틴아메리카
  • 유럽
  • 동아시아
  • 남아시아
  • 오세아니아
  • 중동 및 아프리카
• 지역별 시장의 매력 분석

제13장 북미의 허혈성 시신경증 치료 시장 분석

제14장 라틴아메리카의 허혈성 시신경증 치료 시장 분석

제15장 유럽의 허혈성 시신경증 치료 시장 분석

제16장 동아시아의 허혈성 시신경증 치료 시장 분석

제17장 남아시아의 허혈성 시신경증 치료 시장 분석

제18장 오세아니아의 허혈성 시신경증 치료 시장

제19장 중동 및 아프리카의 허혈성 시신경증 치료 시장 분석

제20장 시장 구조 분석

• 기업계층별 시장 분석
• 주요 기업의 시장 점유율 분석
• 시장현재분석

제21장 경쟁 분석

• 경쟁 대시보드
• 경쟁의 상세
  • AbbVie Inc.(Allergan plc)
  • Eli Lilly and Company
  • GlaxoSmithKline plc.
  • Pfizer Inc.
  • Teva Pharmaceuticals
  • Bausch Health Companies Inc.
  • Bayer AG
  • Bristol-Myers Squibb and Company
  • Sanofi SA
  • F. Hoffmann-La Roche Ltd

제22장 전제와 약어

제23장 조사 방법

BJH

영문 목차

영문목차

Persistence Market Research has recently released a comprehensive report on the Ischemic Optic Neuropathy Treatment Market. The report offers a thorough assessment of crucial market dynamics, including drivers, trends, opportunities, and challenges, providing detailed insights into the market structure.

Key Insights:

• Ischemic Optic Neuropathy Treatment Market Size (2024E): USD 213.7 Mn
• Projected Market Value (2033F): USD 286.6 Mn
• Global Market Growth Rate (CAGR 2024 to 2033): 3.3%

Ischemic Optic Neuropathy Treatment Market - Report Scope:

Ischemic Optic Neuropathy (ION) refers to a condition involving the insufficient blood flow to the optic nerve, leading to vision loss. The market for ION treatments caters to hospitals, clinics, specialized ophthalmology centers, and research institutions, offering a range of therapeutic approaches including pharmacological interventions, surgical procedures, and rehabilitative therapies.

Market Growth Drivers:

The global Ischemic Optic Neuropathy Treatment Market is driven by several factors, including the aging population susceptible to vascular diseases, increasing prevalence of diabetes and hypertension, which are major risk factors for ION, and advancements in diagnostic imaging techniques facilitating early detection and intervention. Moreover, growing awareness among healthcare providers about the efficacy of novel treatments and patient-centric care models further stimulate market expansion.

Market Restraints:

Despite promising growth prospects, the Ischemic Optic Neuropathy Treatment Market faces challenges related to limited treatment options, high costs associated with advanced therapies, and varying reimbursement policies across different regions. Additionally, the complexity of the disease pathology and the need for personalized treatment approaches pose challenges for market penetration and treatment standardization.

Market Opportunities:

The Ischemic Optic Neuropathy Treatment Market presents significant growth opportunities driven by ongoing research and development initiatives focused on novel therapeutic targets, including neuroprotective agents and gene therapies. Furthermore, collaborations between pharmaceutical companies, academic institutions, and healthcare providers to advance clinical trials and innovative treatment modalities are poised to enhance market dynamics and patient outcomes.

Key Questions Answered in the Report:

• What are the primary factors driving the growth of the Ischemic Optic Neuropathy Treatment Market globally?
• Which therapeutic approaches and emerging technologies are reshaping the competitive landscape of the Ischemic Optic Neuropathy Treatment Market?
• Who are the key players contributing to the Ischemic Optic Neuropathy Treatment Market, and what strategies are they employing to maintain market relevance?
• What are the emerging trends and future prospects in the global Ischemic Optic Neuropathy Treatment Market?

Competitive Intelligence and Business Strategy:

Leading players in the global Ischemic Optic Neuropathy Treatment Market, including major pharmaceutical companies and specialized ophthalmic device manufacturers, focus on innovation, clinical trial advancements, and strategic collaborations to gain a competitive edge. These companies invest in R&D to develop breakthrough therapies, enhance treatment efficacy, and improve patient outcomes. Collaborations with regulatory agencies and patient advocacy groups also play a crucial role in facilitating market access and promoting therapeutic innovations.

Key Companies Profiled:

• AbbVie Inc.
• Eli Lily Company
• GlaxoSmithKline
• Pfizer Inc.
• Teva Pharmaceuticals
• Bausch Health Companies Inc.
• F. Hoffmann-La Roche AG
• Bayer AG
• Sanofi A.S.
• Bristol-Myers Squibb and Company

Key Segments Covered in Ischemic Optic Neuropathy Treatment Industry Research

Drug Class:

• Corticosteroids
• Antimetabolites
• Anticoagulants
• Serotonin and norepinephrine reuptake inhibitors (SNRIs)
• Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)

Route of Administration:

• Oral
• Injectable

Disease Type:

• Posterior ischemic optic neuropathy
• Anterior ischemic optic neuropathy

Distribution Channel:

• Hospital Pharmacies
• Retail Pharmacies
• Drug Stores
• Online Pharmacies

Region:

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East & Africa

Table of Contents

1. Executive Summary

• 1.1. Global Market Outlook
• 1.2. Demand Side Trends
• 1.3. Supply Side Trends
• 1.4. Analysis and Recommendations

2. Market Overview

• 2.1. Market Coverage / Taxonomy
• 2.2. Market Definition / Scope / Limitations
• 2.3. Inclusions and Exclusions

3. Key Market Trends

• 3.1. Key Trends Impacting the Market
• 3.2. Innovation / Development Trends

4. Key Success Factors

• 4.1. Drug Class Adoption Analysis
• 4.2. Key Regulations
• 4.3. Pipeline Assessment
• 4.4. Key promotional Strategies, By Key Players
• 4.5. PESTEL Analysis
• 4.6. Porter's Analysis
• 4.7. Value Chain Analysis

5. Market Background

• 5.1. Macro-Economic Factors
  • 5.1.1. Global GDP Growth Outlook
  • 5.1.2. Global Healthcare Outlook
  • 5.1.3. Global Ophthalmic Disease Therapeutics Market Outlook
• 5.2. Forecast Factors - Relevance & Impact
  • 5.2.1. Increase in R&D Spending
  • 5.2.2. Growing Lifestyle Disease Prevalence
  • 5.2.3. Cost of Drug Class
  • 5.2.4. Drug Class Adoption Rate
  • 5.2.5. New Drug Class pipeline
  • 5.2.6. Recent Drug Class Launched/approved
  • 5.2.7. Changes in Regulatory Policies
• 5.3. Market Dynamics
  • 5.3.1. Drivers
  • 5.3.2. Restraints
  • 5.3.3. Opportunity Analysis

6. COVID-19 Crisis Analysis

• 6.1. COVID-19 and Impact Analysis
  • 6.1.1. By Drug Class
  • 6.1.2. By Route of Administration
  • 6.1.3. By Disease Type
  • 6.1.4. By Distribution Channel
  • 6.1.5. By Country
• 6.2. 2024 Market Scenario

7. Global Ischemic Optic Neuropathy Treatment Market Demand (in Value or Size in US$ Mn) Analysis 2019-2023 and Forecast, 2024-2033

• 7.1. Historical Market Value (US$ Mn) Analysis, 2019-2023
• 7.2. Current and Future Market Value (US$ Mn) Projections, 2024-2033
  • 7.2.1. Y-o-Y Growth Trend Analysis
  • 7.2.2. Absolute $ Opportunity Analysis

8. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Drug Class

• 8.1. Introduction / Key Findings
• 8.2. Historical Market Size (US$ Mn) Analysis, By Drug Class, 2019-2023
• 8.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Drug Class, 2024-2033
  • 8.3.1. Corticosteroids
  • 8.3.2. Antimetabolites
  • 8.3.3. Anticoagulants
  • 8.3.4. Serotonin and norepinephrine reuptake inhibitors (SNRIs)
  • 8.3.5. Nonsteroidal Anti-Inflammatory Drugs (NSAIDs)
• 8.4. Market Attractiveness Analysis By Drug Class

9. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Route of Administration

• 9.1. Introduction / Key Findings
• 9.2. Historical Market Size (US$ Mn) Analysis, By Route of Administration, 2019-2023
• 9.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Route of Administration, 2024-2033
  • 9.3.1. Oral
  • 9.3.2. Injectable
• 9.4. Market Attractiveness Analysis By Route of Administration

10. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Disease Type

• 10.1. Introduction / Key Findings
• 10.2. Historical Market Size (US$ Mn) Analysis, By Disease Type, 2019-2023
• 10.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Disease Type, 2024-2033
  • 10.3.1. Posterior ischemic optic neuropathy
  • 10.3.2. Anterior ischemic optic neuropathy
    • 10.3.2.1. Arteritic AION (A-AION)
    • 10.3.2.2. Non-Arteritic AION (NA-AION)
• 10.4. Market Attractiveness Analysis By Disease Type

11. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Distribution Channel

• 11.1. Introduction / Key Findings
• 11.2. Historical Market Size (US$ Mn) Analysis, By Distribution Channel, 2019-2023
• 11.3. Current and Future Market Size (US$ Mn) Analysis and Forecast By Distribution Channel, 2024-2033
  • 11.3.1. Hospital Pharmacies
  • 11.3.2. Retail Pharmacies
  • 11.3.3. Drug Stores
  • 11.3.4. Online Pharmacies
• 11.4. Market Attractiveness Analysis By Distribution Channel

12. Global Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033, By Region

• 12.1. Introduction
• 12.2. Historical Market Size (US$ Mn) Analysis By Region, 2019-2023
• 12.3. Current and Future Market Value (US$ Mn) Analysis and Forecast, By Region 2024-2033
  • 12.3.1. North America
  • 12.3.2. Latin America
  • 12.3.3. Europe
  • 12.3.4. East Asia
  • 12.3.5. South Asia
  • 12.3.6. Oceania
  • 12.3.7. Middle East and Africa (MEA)
• 12.4. Market Attractiveness Analysis By Region

13. North America Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

• 13.1. Introduction
• 13.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 13.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 13.3.1. By Country
    • 13.3.1.1. U.S.
    • 13.3.1.2. Canada
  • 13.3.2. By Drug Class
  • 13.3.3. By Route of Administration
  • 13.3.4. By Disease Type
  • 13.3.5. By Distribution Channel
• 13.4. Market Attractiveness Analysis
  • 13.4.1. By Country
  • 13.4.2. By Drug Class
  • 13.4.3. By Route of Administration
  • 13.4.4. By Disease Type
  • 13.4.5. By Distribution Channel
• 13.5. Market Trends
• 13.6. Drivers and Restraints - Impact Analysis
• 13.7. Key Players - Intensity Mapping
• 13.8. Country Level Analysis & Forecast
  • 13.8.1. U.S. Ischemic Optic Neuropathy Treatment Market Analysis
    • 13.8.1.1. Introduction
    • 13.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.1.2.1. By Drug Class
      • 13.8.1.2.2. By Route of Administration
      • 13.8.1.2.3. By Disease Type
      • 13.8.1.2.4. By Distribution Channel
  • 13.8.2. Canada Ischemic Optic Neuropathy Treatment Market Analysis
    • 13.8.2.1. Introduction
    • 13.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 13.8.2.2.1. By Drug Class
      • 13.8.2.2.2. By Route of Administration
      • 13.8.2.2.3. By Disease Type
      • 13.8.2.2.4. By Distribution Channel

14. Latin America Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

• 14.1. Introduction
• 14.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 14.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 14.3.1. By Country
    • 14.3.1.1. Mexico
    • 14.3.1.2. Brazil
    • 14.3.1.3. Argentina
    • 14.3.1.4. Rest of Latin America
  • 14.3.2. By Drug Class
  • 14.3.3. By Route of Administration
  • 14.3.4. By Disease Type
  • 14.3.5. By Distribution Channel
• 14.4. Market Attractiveness Analysis
  • 14.4.1. By Country
  • 14.4.2. By Drug Class
  • 14.4.3. By Route of Administration
  • 14.4.4. By Disease Type
  • 14.4.5. By Distribution Channel
• 14.5. Market Trends
• 14.6. Drivers and Restraints - Impact Analysis
• 14.7. Key Players - Intensity Mapping
• 14.8. Country Level Analysis & Forecast
  • 14.8.1. Mexico Ischemic Optic Neuropathy Treatment Market Analysis
    • 14.8.1.1. Introduction
    • 14.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.1.2.1. By Drug Class
      • 14.8.1.2.2. By Route of Administration
      • 14.8.1.2.3. By Disease Type
      • 14.8.1.2.4. By Distribution Channel
  • 14.8.2. Brazil Ischemic Optic Neuropathy Treatment Market Analysis
    • 14.8.2.1. Introduction
    • 14.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.2.2.1. By Drug Class
      • 14.8.2.2.2. By Route of Administration
      • 14.8.2.2.3. By Disease Type
      • 14.8.2.2.4. By Distribution Channel
  • 14.8.3. Argentina Ischemic Optic Neuropathy Treatment Market Analysis
    • 14.8.3.1. Introduction
    • 14.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 14.8.3.2.1. By Drug Class
      • 14.8.3.2.2. By Route of Administration
      • 14.8.3.2.3. By Disease Type
      • 14.8.3.2.4. By Distribution Channel

15. Europe Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

• 15.1. Introduction
• 15.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 15.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 15.3.1. By Country
    • 15.3.1.1. Germany
    • 15.3.1.2. Italy
    • 15.3.1.3. France
    • 15.3.1.4. U.K.
    • 15.3.1.5. Spain
    • 15.3.1.6. BENELUX
    • 15.3.1.7. Russia
    • 15.3.1.8. Rest of Europe
  • 15.3.2. By Drug Class
  • 15.3.3. By Route of Administration
  • 15.3.4. By Disease Type
  • 15.3.5. By Distribution Channel
• 15.4. Market Attractiveness Analysis
  • 15.4.1. By Country
  • 15.4.2. By Drug Class
  • 15.4.3. By Route of Administration
  • 15.4.4. By Disease Type
  • 15.4.5. By Distribution Channel
• 15.5. Market Trends
• 15.6. Drivers and Restraints - Impact Analysis
• 15.7. Key Players - Intensity Mapping
• 15.8. Country Level Analysis & Forecast
  • 15.8.1. Germany Ischemic Optic Neuropathy Treatment Market Analysis
    • 15.8.1.1. Introduction
    • 15.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.1.2.1. By Drug Class
      • 15.8.1.2.2. By Route of Administration
      • 15.8.1.2.3. By Disease Type
      • 15.8.1.2.4. By Distribution Channel
  • 15.8.2. Italy Ischemic Optic Neuropathy Treatment Market Analysis
    • 15.8.2.1. Introduction
    • 15.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.2.2.1. By Drug Class
      • 15.8.2.2.2. By Route of Administration
      • 15.8.2.2.3. By Disease Type
      • 15.8.2.2.4. By Distribution Channel
  • 15.8.3. France Ischemic Optic Neuropathy Treatment Market Analysis
    • 15.8.3.1. Introduction
    • 15.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.3.2.1. By Drug Class
      • 15.8.3.2.2. By Route of Administration
      • 15.8.3.2.3. By Disease Type
      • 15.8.3.2.4. By Distribution Channel
  • 15.8.4. U.K. Ischemic Optic Neuropathy Treatment Market Analysis
    • 15.8.4.1. Introduction
    • 15.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.4.2.1. By Drug Class
      • 15.8.4.2.2. By Route of Administration
      • 15.8.4.2.3. By Disease Type
      • 15.8.4.2.4. By Distribution Channel
  • 15.8.5. Spain Ischemic Optic Neuropathy Treatment Market Analysis
    • 15.8.5.1. Introduction
    • 15.8.5.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.5.2.1. By Drug Class
      • 15.8.5.2.2. By Route of Administration
      • 15.8.5.2.3. By Disease Type
      • 15.8.5.2.4. By Distribution Channel
  • 15.8.6. BENELUX Ischemic Optic Neuropathy Treatment Market Analysis
    • 15.8.6.1. Introduction
    • 15.8.6.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.6.2.1. By Drug Class
      • 15.8.6.2.2. By Route of Administration
      • 15.8.6.2.3. By Disease Type
      • 15.8.6.2.4. By Distribution Channel
  • 15.8.7. Russia Ischemic Optic Neuropathy Treatment Market Analysis
    • 15.8.7.1. Introduction
    • 15.8.7.2. Market Analysis and Forecast by Market Taxonomy
      • 15.8.7.2.1. By Drug Class
      • 15.8.7.2.2. By Route of Administration
      • 15.8.7.2.3. By Disease Type
      • 15.8.7.2.4. By Distribution Channel

16. East Asia Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

• 16.1. Introduction
• 16.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 16.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 16.3.1. By Country
    • 16.3.1.1. China
    • 16.3.1.2. Japan
    • 16.3.1.3. South Korea
  • 16.3.2. By Drug Class
  • 16.3.3. By Route of Administration
  • 16.3.4. By Disease Type
  • 16.3.5. By Distribution Channel
• 16.4. Market Attractiveness Analysis
  • 16.4.1. By Country
  • 16.4.2. By Drug Class
  • 16.4.3. By Route of Administration
  • 16.4.4. By Disease Type
  • 16.4.5. By Distribution Channel
• 16.5. Market Trends
• 16.6. Drivers and Restraints - Impact Analysis
• 16.7. Key Players - Intensity Mapping
• 16.8. Country Level Analysis & Forecast
  • 16.8.1. China Ischemic Optic Neuropathy Treatment Market Analysis
    • 16.8.1.1. Introduction
    • 16.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.1.2.1. By Drug Class
      • 16.8.1.2.2. By Route of Administration
      • 16.8.1.2.3. By Disease Type
      • 16.8.1.2.4. By Distribution Channel
  • 16.8.2. Japan Ischemic Optic Neuropathy Treatment Market Analysis
    • 16.8.2.1. Introduction
    • 16.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.2.2.1. By Drug Class
      • 16.8.2.2.2. By Route of Administration
      • 16.8.2.2.3. By Disease Type
      • 16.8.2.2.4. By Distribution Channel
  • 16.8.3. South Korea Ischemic Optic Neuropathy Treatment Market Analysis
    • 16.8.3.1. Introduction
    • 16.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 16.8.3.2.1. By Drug Class
      • 16.8.3.2.2. By Route of Administration
      • 16.8.3.2.3. By Disease Type
      • 16.8.3.2.4. By Distribution Channel

17. South Asia Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

• 17.1. Introduction
• 17.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 17.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 17.3.1. By Country
    • 17.3.1.1. India
    • 17.3.1.2. Indonesia
    • 17.3.1.3. Malaysia
    • 17.3.1.4. Thailand
    • 17.3.1.5. Rest of South Asia
  • 17.3.2. By Drug Class
  • 17.3.3. By Route of Administration
  • 17.3.4. By Disease Type
  • 17.3.5. By Distribution Channel
• 17.4. Market Attractiveness Analysis
  • 17.4.1. By Country
  • 17.4.2. By Drug Class
  • 17.4.3. By Route of Administration
  • 17.4.4. By Disease Type
  • 17.4.5. By Distribution Channel
• 17.5. Market Trends
• 17.6. Drivers and Restraints - Impact Analysis
• 17.7. Key Players - Intensity Mapping
• 17.8. Country Level Analysis & Forecast
  • 17.8.1. India Ischemic Optic Neuropathy Treatment Market Analysis
    • 17.8.1.1. Introduction
    • 17.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.1.2.1. By Drug Class
      • 17.8.1.2.2. By Route of Administration
      • 17.8.1.2.3. By Disease Type
      • 17.8.1.2.4. By Distribution Channel
  • 17.8.2. Indonesia Ischemic Optic Neuropathy Treatment Market Analysis
    • 17.8.2.1. Introduction
    • 17.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.2.2.1. By Drug Class
      • 17.8.2.2.2. By Route of Administration
      • 17.8.2.2.3. By Disease Type
      • 17.8.2.2.4. By Distribution Channel
  • 17.8.3. Malaysia Ischemic Optic Neuropathy Treatment Market Analysis
    • 17.8.3.1. Introduction
    • 17.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.3.2.1. By Drug Class
      • 17.8.3.2.2. By Route of Administration
      • 17.8.3.2.3. By Disease Type
      • 17.8.3.2.4. By Distribution Channel
  • 17.8.4. Thailand Ischemic Optic Neuropathy Treatment Market Analysis
    • 17.8.4.1. Introduction
    • 17.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 17.8.4.2.1. By Drug Class
      • 17.8.4.2.2. By Route of Administration
      • 17.8.4.2.3. By Disease Type
      • 17.8.4.2.4. By Distribution Channel

18. Oceania Ischemic Optic Neuropathy Treatment Market 2019-2023 and Forecast 2024-2033

• 18.1. Introduction
• 18.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 18.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 18.3.1. By Country
    • 18.3.1.1. Australia
    • 18.3.1.2. New Zealand
  • 18.3.2. By Drug Class
  • 18.3.3. By Route of Administration
  • 18.3.4. By Disease Type
  • 18.3.5. By Distribution Channel
• 18.4. Market Attractiveness Analysis
  • 18.4.1. By Country
  • 18.4.2. By Drug Class
  • 18.4.3. By Route of Administration
  • 18.4.4. By Disease Type
  • 18.4.5. By Distribution Channel
• 18.5. Market Trends
• 18.6. Drivers and Restraints - Impact Analysis
• 18.7. Key Players - Intensity Mapping
• 18.8. Country Level Analysis & Forecast
  • 18.8.1. Australia Ischemic Optic Neuropathy Treatment Market Analysis
    • 18.8.1.1. Introduction
    • 18.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.1.2.1. By Drug Class
      • 18.8.1.2.2. By Route of Administration
      • 18.8.1.2.3. By Disease Type
      • 18.8.1.2.4. By Distribution Channel
  • 18.8.2. New Zealand Ischemic Optic Neuropathy Treatment Market Analysis
    • 18.8.2.1. Introduction
    • 18.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 18.8.2.2.1. By Drug Class
      • 18.8.2.2.2. By Route of Administration
      • 18.8.2.2.3. By Disease Type
      • 18.8.2.2.4. By Distribution Channel

19. Middle East and Africa (MEA) Ischemic Optic Neuropathy Treatment Market Analysis 2019-2023 and Forecast 2024-2033

• 19.1. Introduction
• 19.2. Historical Market Size (US$ Mn) Trend Analysis By Market Taxonomy, 2019-2023
• 19.3. Current and Future Market Value (US$ Mn) Analysis and Forecast Analysis By Market Taxonomy, 2024-2033
  • 19.3.1. By Country
    • 19.3.1.1. GCC Countries
    • 19.3.1.2. Turkey
    • 19.3.1.3. North Africa
    • 19.3.1.4. South Africa
    • 19.3.1.5. Rest of Middle East and Africa
  • 19.3.2. By Drug Class
  • 19.3.3. By Route of Administration
  • 19.3.4. By Disease Type
  • 19.3.5. By Distribution Channel
• 19.4. Market Attractiveness Analysis
  • 19.4.1. By Country
  • 19.4.2. By Drug Class
  • 19.4.3. By Route of Administration
  • 19.4.4. By Disease Type
  • 19.4.5. By Distribution Channel
• 19.5. Market Trends
• 19.6. Drivers and Restraints - Impact Analysis
• 19.7. Key Players - Intensity Mapping
• 19.8. Country Level Analysis & Forecast
  • 19.8.1. GCC Countries Ischemic Optic Neuropathy Treatment Market Analysis
    • 19.8.1.1. Introduction
    • 19.8.1.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.1.2.1. By Drug Class
      • 19.8.1.2.2. By Route of Administration
      • 19.8.1.2.3. By Disease Type
      • 19.8.1.2.4. By Distribution Channel
  • 19.8.2. Turkey Ischemic Optic Neuropathy Treatment Market Analysis
    • 19.8.2.1. Introduction
    • 19.8.2.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.2.2.1. By Drug Class
      • 19.8.2.2.2. By Route of Administration
      • 19.8.2.2.3. By Disease Type
      • 19.8.2.2.4. By Distribution Channel
  • 19.8.3. South Africa Ischemic Optic Neuropathy Treatment Market Analysis
    • 19.8.3.1. Introduction
    • 19.8.3.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.3.2.1. By Drug Class
      • 19.8.3.2.2. By Route of Administration
      • 19.8.3.2.3. By Disease Type
      • 19.8.3.2.4. By Distribution Channel
  • 19.8.4. North Africa Ischemic Optic Neuropathy Treatment Market Analysis
    • 19.8.4.1. Introduction
    • 19.8.4.2. Market Analysis and Forecast by Market Taxonomy
      • 19.8.4.2.1. By Drug Class
      • 19.8.4.2.2. By Route of Administration
      • 19.8.4.2.3. By Disease Type
      • 19.8.4.2.4. By Distribution Channel

20. Market Structure Analysis

• 20.1. Market Analysis by Tier of Companies
• 20.2. Market Share Analysis of Top Players
• 20.3. Market Presence Analysis

21. Competition Analysis

• 21.1. Competition Dashboard
• 21.2. Competition Deep Dive
  • 21.2.1. AbbVie Inc. (Allergan plc)
    • 21.2.1.1. Overview
    • 21.2.1.2. Drug Class Portfolio
    • 21.2.1.3. Sales Footprint
    • 21.2.1.4. Key Financials
    • 21.2.1.5. SWOT Analysis
    • 21.2.1.6. Strategy Overview
      • 21.2.1.6.1. Marketing Strategy
      • 21.2.1.6.2. Service Strategy
      • 21.2.1.6.3. Channel Strategy
  • 21.2.2. Eli Lilly and Company
    • 21.2.2.1. Overview
    • 21.2.2.2. Drug Class Portfolio
    • 21.2.2.3. Sales Footprint
    • 21.2.2.4. Key Financials
    • 21.2.2.5. SWOT Analysis
    • 21.2.2.6. Strategy Overview
      • 21.2.2.6.1. Marketing Strategy
      • 21.2.2.6.2. Service Strategy
      • 21.2.2.6.3. Channel Strategy
  • 21.2.3. GlaxoSmithKline plc.
    • 21.2.3.1. Overview
    • 21.2.3.2. Drug Class Portfolio
    • 21.2.3.3. Sales Footprint
    • 21.2.3.4. Key Financials
    • 21.2.3.5. SWOT Analysis
    • 21.2.3.6. Strategy Overview
      • 21.2.3.6.1. Marketing Strategy
      • 21.2.3.6.2. Service Strategy
      • 21.2.3.6.3. Channel Strategy
  • 21.2.4. Pfizer Inc.
    • 21.2.4.1. Overview
    • 21.2.4.2. Drug Class Portfolio
    • 21.2.4.3. Sales Footprint
    • 21.2.4.4. Key Financials
    • 21.2.4.5. SWOT Analysis
    • 21.2.4.6. Strategy Overview
      • 21.2.4.6.1. Marketing Strategy
      • 21.2.4.6.2. Service Strategy
      • 21.2.4.6.3. Channel Strategy
  • 21.2.5. Teva Pharmaceuticals
    • 21.2.5.1. Overview
    • 21.2.5.2. Drug Class Portfolio
    • 21.2.5.3. Sales Footprint
    • 21.2.5.4. Key Financials
    • 21.2.5.5. SWOT Analysis
    • 21.2.5.6. Strategy Overview
      • 21.2.5.6.1. Marketing Strategy
      • 21.2.5.6.2. Service Strategy
      • 21.2.5.6.3. Channel Strategy
  • 21.2.6. Bausch Health Companies Inc.
    • 21.2.6.1. Overview
    • 21.2.6.2. Drug Class Portfolio
    • 21.2.6.3. Sales Footprint
    • 21.2.6.4. Key Financials
    • 21.2.6.5. SWOT Analysis
    • 21.2.6.6. Strategy Overview
      • 21.2.6.6.1. Marketing Strategy
      • 21.2.6.6.2. Service Strategy
      • 21.2.6.6.3. Channel Strategy
  • 21.2.7. Bayer AG
    • 21.2.7.1. Overview
    • 21.2.7.2. Drug Class Portfolio
    • 21.2.7.3. Sales Footprint
    • 21.2.7.4. Key Financials
    • 21.2.7.5. SWOT Analysis
    • 21.2.7.6. Strategy Overview
      • 21.2.7.6.1. Marketing Strategy
      • 21.2.7.6.2. Service Strategy
      • 21.2.7.6.3. Channel Strategy
  • 21.2.8. Bristol-Myers Squibb and Company
    • 21.2.8.1. Overview
    • 21.2.8.2. Drug Class Portfolio
    • 21.2.8.3. Sales Footprint
    • 21.2.8.4. Key Financials
    • 21.2.8.5. SWOT Analysis
    • 21.2.8.6. Strategy Overview
      • 21.2.8.6.1. Marketing Strategy
      • 21.2.8.6.2. Service Strategy
      • 21.2.8.6.3. Channel Strategy
  • 21.2.9. Sanofi S.A.
    • 21.2.9.1. Overview
    • 21.2.9.2. Drug Class Portfolio
    • 21.2.9.3. Sales Footprint
    • 21.2.9.4. Key Financials
    • 21.2.9.5. SWOT Analysis
    • 21.2.9.6. Strategy Overview
      • 21.2.9.6.1. Marketing Strategy
      • 21.2.9.6.2. Service Strategy
      • 21.2.9.6.3. Channel Strategy
  • 21.2.10. F. Hoffmann-La Roche Ltd
    • 21.2.10.1. Overview
    • 21.2.10.2. Drug Class Portfolio
    • 21.2.10.3. Sales Footprint
    • 21.2.10.4. Key Financials
    • 21.2.10.5. SWOT Analysis
    • 21.2.10.6. Strategy Overview
      • 21.2.10.6.1. Marketing Strategy
      • 21.2.10.6.2. Service Strategy
      • 21.2.10.6.3. Channel Strategy

22. Assumptions and Acronyms Used

23. Research Methodology

관련자료